An emerging philosophy of medicine in the 21st century is personalization of care. Critical factors in accomplishing this are to understand the genetic profile of the patient as well as the genetic profile and the clinicopathologic features of the disease affecting the patient. Progress has been made in defining the genetic alterations associated with differentiated thyroid cancers (DTCs). Unfortunately, the genetic profile of a DTC currently does not play a role in determining the extent of therapy for an individual patient with such a cancer.
Smith RB, Ferris RL. Utility of Diagnostic Molecular Markers for Evaluation of Indeterminate Thyroid Nodules. JAMA Otolaryngol Head Neck Surg. 2016;142(5):421–422. doi:10.1001/jamaoto.2016.0142
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: